AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04119726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based counselling
Description: The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database
Study NCT02676076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 100/6/12.5 µg
Study NCT02676076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 100/6 µg
Study NCT02361203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
Study NCT01453153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
Study NCT01453153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
Study NCT01453153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: (Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
Study NCT01453153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: (Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
Study NCT05247931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine
Description: Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
Study NCT00363805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea
Description: Given orally
Study NCT00363805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Given orally
Study NCT00363805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03653611 — intervention group
Intervention type: OTHER
Intervention: On-site Practice Assessment
Description: The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
Study NCT01291004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day levonorgestrel oral contraceptive
Description: Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
Study NCT02981186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of hydrophobic material
Study NCT01895062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Management System (AMS)
Description: The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway.
Study NCT02981186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation comparator
Description: Implantation of trifocal IOL POD F consisting of hydrophilic material
Study NCT02054299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Amitriptyline
Description: Amitriptyline: 25 mg, single oral application
Study NCT02021578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Cognitive Behavioral Prevention
Description: Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
Study NCT02054299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Desvenlafaxine
Description: Desvenlafaxine: 50 mg, single oral application
Study NCT02054299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Sumatriptan
Description: Sumatriptan: 50 mg, single oral application
Study NCT02054299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Proguanil
Description: Proguanil: 200mg, single oral application
Study NCT02054299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Fenoterol
Description: Fenoterol: 180 mcg, single intravenous application
Study NCT02054299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Thiamine
Description: Thiamine: 200mg, single oral application
Study NCT00828672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered on days 15,22,29,36 en 43; 50 mg/m2
Study NCT00828672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered on days 1,15,29 and 43 ; 5mg/kg
Study NCT00828672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Study NCT00828672 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Total dose 45Gy
Study NCT03901729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1753011
Description: Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
Study NCT03901729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo BAY 1753011
Description: Tablet; Once daily in the morning; Oral
Study NCT03901729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BAY 1753011
Description: Tablet; Once daily in the morning; Oral
Study NCT03901729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Tablet; 40mg unit; 80mg once daily in the morning; Oral
Study NCT03901729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Furosemide
Description: Tablet; Once daily in the morning; Oral
Study NCT00641381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
Study NCT00641381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 100 mg/kg on day -2 prior to stem cell reinfusion
Study NCT00641381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg on day -4 prior to stem cell reinfusion
Study NCT02021578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written information
Description: Reading materials about depression
Study NCT00641381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
Study NCT00641381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Reinfusion of autologous stem cells
Study NCT00641381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Reinfusion of autologous stem cells
Study NCT01006746 — intervention group
Intervention type: OTHER
Intervention: Remote monitoring by Home Monitoring system
Description: Standard of care completed with remote monitoring for ICD patients follow-up
Study NCT04180267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-magnitude High-frequency Vibration
Description: 35Hz, 0.3g, 20min/day, at least 3 times/week
Study NCT01105884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
Study NCT01105884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biatin Ag (Foam)
Description: All the subjects will be treated with Biatin Ag (Foam)
Study NCT01105884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocolloid
Description: All the subjects in this group will be treated with Hydrocolloid
Study NCT01105884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: All the subjects in this group will be treated with Hydrogel
Study NCT03653611 — intervention group
Intervention type: OTHER
Intervention: Clinical Staff Questionnaires
Description: Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff.
Study NCT03653611 — intervention group
Intervention type: OTHER
Intervention: Patient Opinion Surveys
Description: 200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
Study NCT03653611 — intervention group
Intervention type: OTHER
Intervention: Modular online COPD Education
Description: Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
Study NCT03653611 — intervention group
Intervention type: OTHER
Intervention: COPD in Primary Care/CAPTURE Introduction Focus Groups
Description: Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
Study NCT02115815 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
Study NCT02115815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV sF 20 mcg
Description: Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
Study NCT02115815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510 (20 mcg RSV sF)
Description: Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
Study NCT02115815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV sF 50 mcg
Description: Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
Study NCT02115815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510 (50 mcg RSV sF)
Description: Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
Study NCT02115815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV sF 80 mcg
Description: Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
Study NCT02115815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510 (80 mcg RSV sF)
Description: Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
Study NCT01194557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnostic test
Description: Diagnosis of malaria using rapid diagnostic test
Study NCT01194557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumartem
Description: Presumptive treatment of malaria/fever
Study NCT02114671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir high dose
Description: capsules, oral
Study NCT02114671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, oral
Study NCT02114671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: tablets, oral
Study NCT02114671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir low dose
Description: capsules, oral
Study NCT00533897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
Study NCT00533897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
Study NCT03423082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine
Description: Each subject will receive one IV dose of 18F fluciclovine for PET scanning
Study NCT03423082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine PET
Description: Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
Study NCT01105884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceredak
Description: All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
Study NCT02028130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAA electrical isolation + occlusion
Description: LAA electrical isolation + Watchman device implantation to occlude LAA
Study NCT02742142 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water as placebo
Description: topical application of water as a placebo in the control arm
Study NCT02742142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diammine fluoride
Description: topical application of the SDF solution onto tooth root surfaces
Study NCT03684889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-huCAR19v1
Description: 1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
Study NCT03684889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-huCAR19v2
Description: Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
Study NCT03068949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluBlok
Description: FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
Study NCT03068949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
Study NCT03068949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluCelVax
Description: FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
Study NCT03068949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD
Description: Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly
Study NCT00785096 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire, complications, grading severity, visual analog scale
Study NCT04502498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lower limb duplex & doppler
Description: Lower limb duplex and doppler one week before radical cystectomy
Study NCT01241682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC + CTX
Description: 3x 50x10e6 DC + cyclophosphamide
Study NCT01319435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of biological samples
Description: Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces
Study NCT00637676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS, Talc-Pleurodesis, tunneled pleural drainage
Description: poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
Study NCT05085834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate
Description: Two 45 mg capsules once daily
Study NCT05085834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules once daily
Study NCT03728478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
Study NCT03728478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
Study NCT03728478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injections
Description: Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
Study NCT01416337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: 2 mg single dose tablet on Day 1 of study
Study NCT01416337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212B
Description: A single administration of a slow 1 minute IV push on Day 1.
Study NCT03232567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoVAX
Description: Single ascending dose study
Study NCT03232567 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NasoVAX
Description: Single ascending dose study
Study NCT03592329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Training A
Description: twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions
Study NCT03592329 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Reduction Training A
Description: twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions
Study NCT00637676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS, Talc-pleurodesis
Description: poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
Study NCT03092440 — intervention group
Intervention type: OTHER
Intervention: serious game
Description: During three hours, each learner will play with the three different cases of the LabForGames Warning serious game.
Study NCT03979651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)
Description: Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day
Study NCT03979651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)
Description: Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day
Study NCT03979651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)
Description: Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day
Study NCT02934035 — intervention group
Intervention type: DRUG
Intervention: Antidepressant
Study NCT03308487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 (1000 IU)